These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29167951)

  • 1. Radioembolization Versus Bland Embolization for Hepatic Metastases from Small Intestinal Neuroendocrine Tumors: Short-Term Results of a Randomized Clinical Trial.
    Elf AK; Andersson M; Henrikson O; Jalnefjord O; Ljungberg M; Svensson J; Wängberg B; Johanson V
    World J Surg; 2018 Feb; 42(2):506-513. PubMed ID: 29167951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.
    Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of ADC measurements in predicting overall survival in patients undergoing
    Alis D; Durmaz ESM; Gulsen F; Bas A; Kabasakal L; Sager S; Numan F
    Clin Imaging; 2019; 57():124-130. PubMed ID: 31220677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases.
    Peker A; Çiçek O; Soydal Ç; Küçük NÖ; Bilgiç S
    Diagn Interv Radiol; 2015; 21(1):54-9. PubMed ID: 25430526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional hepatic
    Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
    BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
    Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
    J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravoxel Incoherent Motion Diffusion-Weighted MR Imaging for Prediction of Early Arterial Blood Flow Stasis in Radioembolization of Breast Cancer Liver Metastases.
    Pieper CC; Willinek WA; Meyer C; Ahmadzadehfar H; Kukuk GM; Sprinkart AM; Block W; Schild HH; Mürtz P
    J Vasc Interv Radiol; 2016 Sep; 27(9):1320-1328. PubMed ID: 27402526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioembolization for treatment of liver metastases from neuroendocrine tumors: correlation with imaging and biomarkers.
    Ozao-Choy J; Friedman ML; Kim AS; Wachsman A; Wolin EM; Yu R; Nissen NN; Colquhoun SD
    Pancreas; 2013 Mar; 42(2):358-60. PubMed ID: 23407486
    [No Abstract]   [Full Text] [Related]  

  • 9. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.
    Paprottka PM; Hoffmann RT; Haug A; Sommer WH; Raessler F; Trumm CG; Schmidt GP; Ashoori N; Reiser MF; Jakobs TF
    Cardiovasc Intervent Radiol; 2012 Apr; 35(2):334-42. PubMed ID: 21847708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors.
    Jia Z; Paz-Fumagalli R; Frey G; Sella DM; McKinney JM; Wang W
    J Gastroenterol Hepatol; 2017 Sep; 32(9):1617-1623. PubMed ID: 28132407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic accuracy of diffusion-weighted magnetic resonance imaging versus positron emission tomography/computed tomography for early response assessment of liver metastases to Y90-radioembolization.
    Barabasch A; Kraemer NA; Ciritsis A; Hansen NL; Lierfeld M; Heinzel A; Trautwein C; Neumann U; Kuhl CK
    Invest Radiol; 2015 Jun; 50(6):409-15. PubMed ID: 25763526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative volumetric functional MR imaging: an imaging biomarker of early treatment response in hypo-vascular liver metastasis patients after yttrium-90 transarterial radioembolization.
    Zhu X; Sobhani F; Xu C; Pan L; Ghasebeh MA; Kamel IR
    Abdom Radiol (NY); 2016 Aug; 41(8):1495-504. PubMed ID: 26960726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of response to radio-embolization (TheraSphere®) treatment of neuroendocrine liver metastasis.
    Shaheen M; Hassanain M; Aljiffry M; Cabrera T; Chaudhury P; Simoneau E; Kongkaewpaisarn N; Salman A; Rivera J; Jamal M; Lisbona R; Khankan A; Valenti D; Metrakos P
    HPB (Oxford); 2012 Jan; 14(1):60-6. PubMed ID: 22151453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization.
    Fan KY; Wild AT; Halappa VG; Kumar R; Ellsworth S; Ziegler M; Garg T; Rosati LM; Su Z; Hacker-Prietz A; Pawlik TM; Cosgrove DP; Hong KK; Kamel IR; Geschwind JF; Herman JM
    Contemp Clin Trials; 2016 Sep; 50():143-9. PubMed ID: 27520932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 31P MR spectroscopy to evaluate the efficacy of hepatic artery embolization in the treatment of neuroendocrine liver metastases.
    Ljungberg M; Westberg G; Vikhoff-Baaz B; Starck G; Wängberg B; Ekholm S; Ahlman H; Forssell-Aronsson E
    Acta Radiol; 2012 Dec; 53(10):1118-26. PubMed ID: 23051638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.
    Chen JX; Wileyto EP; Soulen MC
    Trials; 2018 Jul; 19(1):390. PubMed ID: 30016989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases.
    King J; Quinn R; Glenn DM; Janssen J; Tong D; Liaw W; Morris DL
    Cancer; 2008 Sep; 113(5):921-9. PubMed ID: 18618495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study.
    Maire F; Lombard-Bohas C; O'Toole D; Vullierme MP; Rebours V; Couvelard A; Pelletier AL; Zappa M; Pilleul F; Hentic O; Hammel P; Ruszniewski P
    Neuroendocrinology; 2012; 96(4):294-300. PubMed ID: 22507901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apparent diffusion coefficients (ADC) in response assessment of transarterial radioembolization (TARE) for liver metastases of neuroendocrine tumors (NET): a feasibility study.
    Katharina Ingenerf M; Karim H; Fink N; Ilhan H; Ricke J; Treitl KM; Schmid-Tannwald C
    Acta Radiol; 2022 Jul; 63(7):877-888. PubMed ID: 34225464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic neuroendocrine metastases: chemo- or bland embolization?
    Pitt SC; Knuth J; Keily JM; McDermott JC; Weber SM; Chen H; Rilling WS; Quebbeman EJ; Agarwal DM; Pitt HA
    J Gastrointest Surg; 2008 Nov; 12(11):1951-60. PubMed ID: 18709512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.